G. Zwingenberger

MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells

J. Mattes, K. Ebert, B. Luber, 2019, PloS one.

Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF

J. Hasenauer, A. Walch, R. Geffers, 2022, BMC Cancer.

Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

A. Feuchtinger, A. Walch, A. Buck, 2021, Clinical and translational medicine.

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines

J. Hasenauer, D. Maier, S. Keller, 2018, Molecular oncology.

Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines

Fabian J. Theis, Jan Hasenauer, Simone Keller, 2019, bioRxiv.

Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines

J. Hasenauer, R. Geffers, J. Mattes, 2020, BMC Cancer.

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines

W. Weichert, S. Keller, B. Luber, 2016, Journal of Cancer Research and Clinical Oncology.

Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF

J. Hasenauer, A. Walch, R. Geffers, 2022, BMC Cancer.